<DOC>
	<DOCNO>NCT02623751</DOCNO>
	<brief_summary>The primary objective open-label , dose-escalation study investigate safety single-dose monotherapy repeated-dose KHK2375 combine exemestane female subject advance recurrent breast cancer . The secondary objective investigate pharmacokinetics efficacy .</brief_summary>
	<brief_title>Study KHK2375 Subjects With Advanced Recurrent Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Postmenopausal woman age ≥ 20 &lt; 75 year time consent ; Estrogen receptor positive and/or progesterone receptor positive ; HER2negative Nonresectable advance recurrent breast cancer previously treat nonsteroidal aromatase inhibitor ( AI ) , plan treat exemestane Radiation therapy immuno therapy within 14 day first dose investigational product ; Chemotherapy , biological medicine , pharmacotherapy major surgery within 21 day first dose investigational product ; Prior chemotherapy ≥ 3 regimen advanced recurrent breast cancer ; Ongoing treatment investigational product</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>